RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

22 фев 2024 06:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 фев 2024 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

07 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

31 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

12 янв 2024 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640

04 янв 2024 06:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

04 янв 2024 05:58:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

15 дек 2023 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023

13 дек 2023 06:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event

06 дек 2023 06:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update

07 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

02 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

25 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023

17 окт 2023 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 окт 2023 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

10 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

22 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

19 сен 2023 07:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 сен 2023 15:01:00 Источник Nasdaq GlobeNewswire